Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan A Ivanenkov

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Expert Opinion on Therapeutic Patents|July 24, 2012
5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivativesAlexandre V Ivachtchenko, Yan A Ivanenkov
Pharmaceutical Patent Analyst|December 21, 2013
Small-molecule arginase inhibitorsYan A Ivanenkov, Nina V Chufarova
Molecular Pharmaceutics|February 18, 2016
AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's DiseaseAlexandre V Ivachtchenko, Yan Lavrovsky, Yan A Ivanenkov
Journal of Medicinal Chemistry|June 13, 2019
Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?Yan A Ivanenkov, Bogdan A Zagribelnyy, Vladimir A Aladinskiy
Expert Opinion on Therapeutic Patents|September 11, 2012
5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffoldsAlexandre V Ivachtchenko, Yan A Ivanenkov, Andrey V Skorenko
Journal of Chemical Information and Modeling|February 6, 2023
SiteRadar: Utilizing Graph Machine Learning for Precise Mapping of Protein-Ligand-Binding SitesSergei A Evteev, Alexey V Ereshchenko, Yan A Ivanenkov
Expert Opinion on Therapeutic Patents|August 19, 2010
5-hydroxytryptamine subtype 6 receptor modulators: a patent surveyAlexandre V Ivachtchenko, Yan A Ivanenkov, Sergey E Tkachenko
Drug Discovery Today|June 13, 2009
Computational mapping tools for drug discoveryYan A Ivanenkov, Nikolay P Savchuk, Sean Ekins, et al.
Anti-Cancer Agents in Medicinal Chemistry|September 28, 2007
Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspectiveKonstantin V Balakin, Yan A Ivanenkov, Alex S Kiselyov, et al.
Current Alzheimer Research|November 11, 2016
AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal ModelsAlexandre V Ivachtchenko, Yan A Ivanenkov, Mark S Veselov, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Expert Opinion on Therapeutic Patents|July 24, 2012
5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivativesAlexandre V Ivachtchenko, Yan A Ivanenkov
Pharmaceutical Patent Analyst|December 21, 2013
Small-molecule arginase inhibitorsYan A Ivanenkov, Nina V Chufarova
Molecular Pharmaceutics|February 18, 2016
AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's DiseaseAlexandre V Ivachtchenko, Yan Lavrovsky, Yan A Ivanenkov
Journal of Medicinal Chemistry|June 13, 2019
Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?Yan A Ivanenkov, Bogdan A Zagribelnyy, Vladimir A Aladinskiy
Expert Opinion on Therapeutic Patents|September 11, 2012
5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffoldsAlexandre V Ivachtchenko, Yan A Ivanenkov, Andrey V Skorenko
Journal of Chemical Information and Modeling|February 6, 2023
SiteRadar: Utilizing Graph Machine Learning for Precise Mapping of Protein-Ligand-Binding SitesSergei A Evteev, Alexey V Ereshchenko, Yan A Ivanenkov
Expert Opinion on Therapeutic Patents|August 19, 2010
5-hydroxytryptamine subtype 6 receptor modulators: a patent surveyAlexandre V Ivachtchenko, Yan A Ivanenkov, Sergey E Tkachenko
Drug Discovery Today|June 13, 2009
Computational mapping tools for drug discoveryYan A Ivanenkov, Nikolay P Savchuk, Sean Ekins, et al.
Anti-Cancer Agents in Medicinal Chemistry|September 28, 2007
Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspectiveKonstantin V Balakin, Yan A Ivanenkov, Alex S Kiselyov, et al.
Current Alzheimer Research|November 11, 2016
AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal ModelsAlexandre V Ivachtchenko, Yan A Ivanenkov, Mark S Veselov, et al.
Pageof 8